Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
James F. Meschia, M.D., is a neurology researcher who studies stroke. Dr. Meschia's main research interests and goals are to use biochemical and molecular genetic techniques to advance the development of biomarkers to assess risk of stroke and related stroke injury and to identify new drug targets for stroke therapies. Dr. Meschia also leads multicenter randomized clinical trials to advance evidence-based medicine.
About 10% of patients with acute stroke have preexisting dementia, and about 20% will develop dementia within 1 to 2 years after a stroke. Dr. Meschia's research is helping discover blood and imaging biomarkers to create better tools to predict who is at risk of stroke and to develop molecular targets for novel therapies to reduce the risk of cognitive impairment. Currently, the only medical intervention is to focus on preventing recurrent stroke. Ideally, biomarkers for cognitive impairment could be assessed in the acute or subacute period after stroke so that interventions could be initiated to prevent post-stroke dementia.
Learn about clinical trials that address specific scientific questions about human health and disease.
See my studies.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Review my research fingerprint, network, grants, projects, publications, Scopus profile, and Altmetrics scores and badges.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.